"Pharmaceutical patents are extremely valuable and it's for good reason that they're valuable."
"Opponents of reverse settlements have for several years argued that they're anti-competitive."
"Some brand-name manufacturers have chosen to settle lawsuits filed by generics instead of litigating."
"On average, it takes 10 years and $1 billion to develop and gain FDA approval for a new drug."
"Proponents of the agreements have argued that the agreements can never properly be considered anti-competitive."
"Both this recoupment of investment and these profits are jeopardized by lawsuits that are filed by generics."
"I want to talk just a little bit about our use of the term 'pay for delay' today."
"Our laws create a statutory presumption as to the patent's validity."
"But to assume that requires us to assume at the outset that the patent is, in fact, invalid."
"I think you have to presume that the patent is invalid in order, legitimately, to call it pay for delay."
"I agree with the holding of the Supreme Court."
"Wouldn't you have to concede that then in that circumstance you've got pro-competitive effects?"